Abstract
This paper aimed to discuss the denoising ability of magnetic resonance imaging (MRI) images based on fuzzy C-means clustering (FCM) algorithm and the influence of Butylphthalide combined with Edaravone treatment on nerve function and vascular endothelial function in patients with acute cerebral infarction (ACI). Based on FCM algorithm, Markov Random Field (MRF) model algorithm was introduced to obtain a novel algorithm (NFCM), which was compared with FCM and MRF algorithm in terms of misclassification rate (MCR) and difference of Kappa index (KI). 90 patients with ACI diagnosed in hospital from December 2018 to December 2019 were selected as subjects, who were divided into combined treatment group (conventional treatment + Edaravone + Butylphthalide) and Edaravone group (conventional treatment + Edaravone) randomly, each consisting of 45 cases. The National Institutes of Health Stroke Scale (NIHSS) score and endothelial function index level such as plasma nitric oxide (NO), human endothelin-1 (ET-1), and vascular endothelial cell growth factor (VEGF) were compared before and after treatment between the two groups. The results showed that the MCR of NFCM was evidently inferior to FCM and MRF, and the KI was notably higher relative to the other two algorithms. After treatment, the NIHSS score of the combined treatment group was (9.09 ± 1.86) points and that of Edaravone group was (14.97 ± 3.44) points, with evident difference between the two groups (P < 0.05). After treatment, the NO of the combined treatment was (54.63 ± 4.85), and that of Edaravone group was (41.54 ± 5.27), which was considerably different (P < 0.01), and the VEGF and ET-1 of combined treatment group were greatly inferior to Edaravone group (P < 0.01). It was revealed that the novel algorithm based on FCM can obtain more favorable quality and segmentation accuracy of MRI images. Moreover, Butylphthalide combined with Edaravone treatment can effectively improve nerve function, vascular endothelial function, and short-term prognosis in ACI, which was safe and worthy of clinical adoption.
Highlights
acute cerebral infarction (ACI) is a common clinical cerebrovascular disease; together with malignant tumors and heart disease, it is called the “three killers” that endanger human health [1]
A total of 90 patients with ACI who were diagnosed by magnetic resonance imaging (MRI) at XXX Hospital from December 2018 to December 2019 were selected as the research subjects, and the age range was 28–80 years. ey were divided into combined treatment group and Edaravone group by random number table, with 45 cases in each group. e inclusion criteria of this study were as follows
As the noise level continued to increase, the misclassification rate (MCR) values of all algorithms showed an upward trend. e MCR value of new algorithm based on FCM (NFCM) algorithm based on fuzzy C-means clustering (FCM) was absolutely inferior to that of FCM and Markov Random Field (MRF) algorithm
Summary
ACI is a common clinical cerebrovascular disease; together with malignant tumors and heart disease, it is called the “three killers” that endanger human health [1]. ACI has the characteristics of rapid onset, high morbidity and disability, and poor prognosis [2]. E tissues of ACI patients undergo ischemia and hypoxia, which in turn causes the body to produce a large number of free radicals. The cell membrane is damaged, and in severe cases, the brain tissue will be completely necrotic. ACI can cause different degrees of cognitive dysfunction in patients, such as hemiplegia, aphasia, language dysfunction, hemianopia, and memory loss. Erefore, timely diagnosis and treatment of ACI patients is of great significance. The treatment of ACI patients mainly adopts thrombolytic therapy. The actual thrombolysis rate of ACI is very low. E thrombolysis rate in European and American countries is 4.1∼6.3% The actual thrombolysis rate of ACI is very low. e thrombolysis rate in European and American countries is 4.1∼6.3%
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
